x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

1:52

Pharmaceutical Executive Daily: US Senate Passes...

Pharmaceutical Executive ·

2025/12/19

In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for biopharma supply chains, and industry experts examine how rebate consultants are shaping biosimilar adoption.

en-us

1:49

Pharmaceutical Executive Daily: Pfizer's Stock Drops...

Pharmaceutical Executive ·

2025/12/18

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.

en-us

1:33

Pharmaceutical Executive Daily: FDA's Approval of...

Pharmaceutical Executive ·

2025/12/17

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a national priority voucher tied to Tecvayli in multiple myeloma.

en-us

1:37

Pharmaceutical Executive Daily: TrumpRx's Critical...

Pharmaceutical Executive ·

2025/12/16

In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.

en-us

1:53

Pharmaceutical Executive Daily: Retatrutide's...

Pharmaceutical Executive ·

2025/12/15

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.

en-us

1:42

Pharmaceutical Executive Daily: FDA's Approval of...

Pharmaceutical Executive ·

2025/12/11

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.

en-us

1:53

Pharmaceutical Executive Daily: FDA's New Standard...

Pharmaceutical Executive ·

2025/12/10

In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration targeting atopic diseases, and new insights reveal how payers are shaping expectations for Phase III trial design.

en-us

1:48

Pharmaceutical Executive Daily: Carvykti Demonstrates...

Pharmaceutical Executive ·

2025/12/09

In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.

en-us

1:43

Pharmaceutical Executive Daily: FDA Approves Breyanzi

Pharmaceutical Executive ·

2025/12/08

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a head-to-head Phase III trial against Imbruvica for CLL/SLL, and new analyses highlight how health systems are strengthening partnerships to support cell and gene therapy commercialization.

en-us

1:48

Pharmaceutical Executive Daily: Mark Cuban's Push for...

Pharmaceutical Executive ·

2025/12/05

In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory standards, Mark Cuban urges federal officials to waive fees to boost generic drug competition, and a new report reveals patients are increasingly avoiding care due to rising healthcare costs.

en-us

1:49

Pharmaceutical Executive Daily: FDA Names Tracy Beth...

Pharmaceutical Executive ·

2025/12/04

In today’s Pharmaceutical Executive Daily, the FDA appoints Tracy Beth Høeg as acting CDER director, health systems explore new commercialization partnerships for cell and gene therapies, and Aidoc submits a breakthrough-designated multi-triage AI device for FDA approval.

en-us

1:51

Pharmaceutical Executive Daily: FDA's Agentic AI...

Pharmaceutical Executive ·

2025/12/03

In today’s Pharmaceutical Executive Daily, Regeneron launches a $150 million gene editing collaboration with Tessera Therapeutics, the FDA begins agency-wide deployment of new agentic AI tools, and a new report suggests Richard Pazdur is stepping down as director of CDER.

en-us

1:49

Pharmaceutical Executive Daily: Lilly Reduces the...

Pharmaceutical Executive ·

2025/12/02

In today’s Pharmaceutical Executive Daily, Eli Lilly reduces the price of Zepbound single-dose vials for self-pay patients, a new report claims the FDA is planning changes to its vaccine approval process following assertions of COVID vaccine–related deaths, and Korea and Australia reorient their pharma launch strategies toward broader regional market opportunities.

en-us

1:50

Pharmaceutical Executive Daily: U.S. & U.K. Agree to...

Pharmaceutical Executive ·

2025/12/01

In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, the US and UK agree to eliminate tariffs on pharmaceutical products, and CMS publishes major price cuts for 15 high-cost Medicare drugs under the latest IRA negotiation round.

en-us

1:50

Pharmaceutical Executive Daily: Novartis Cuts 550 Jobs

Pharmaceutical Executive ·

2025/11/26

In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular atrophy, and industry experts weigh in on how next-generation CDMOs are evolving to meet rapid market change.

en-us

2:03

Pharmaceutical Executive Daily: Moderna's $1.5...

Pharmaceutical Executive ·

2025/11/25

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes out a $1.5 billion loan to support its long-term growth plan, and Medicare moves closer to releasing negotiated prices for 15 widely used, high-cost medicines.

en-us

2:08

Pharmaceutical Executive Daily: Tesaro and...

Pharmaceutical Executive ·

2025/11/24

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship Pioneering and Valo Health announce major new collaborations, and why integrated direct-to-patient drug distribution is becoming a strategic imperative.

en-us

1:40

Pharmaceutical Executive Daily: Novartis' North...

Pharmaceutical Executive ·

2025/11/21

In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manufacturing hub in North Carolina, and the FDA is rolling out a wide batch of drug approvals.

en-us

1:47

Pharmaceutical Executive Daily: Moderna's $140...

Pharmaceutical Executive ·

2025/11/20

In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new research collaborations under the LTZ Fleming Initiative, and the FDA commissioner highlights how early and late movers can benefit from the National Priority Voucher program.

en-us

1:39

Pharmaceutical Executive Daily: FDA's Approval of...

Pharmaceutical Executive ·

2025/11/19

In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.

en-us

257 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter